Praveen Tipir­neni's team at Mor­phic reels in an $80M round as they turn in­to the last stretch to the clin­ic — and a deal

As a for­mer busi­ness de­vel­op­ment guy at Cu­bist, Praveen Tipir­neni got to know the rou­tine about the due dili­gence work BD teams are known for dur­ing a ne­go­ti­a­tion. 

“Peo­ple poke holes,” he says. It could be about an as­say, some­thing that was be­ing hyped be­yond re­al­i­ty or a pro­gram that was pre­sent­ed at a cer­tain stage which may not quite be there yet.

But you have to find those holes. 

Now that he’s on the CEO side of the bar­gain­ing ta­ble, though, one of on­ly two peo­ple on Mor­phic Ther­a­peu­tic’s 37-mem­ber team not de­vot­ed en­tire­ly to re­search, he’s more than a lit­tle pleased that the part­ners he’s talk­ing with haven’t been balk­ing over any holes.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER